Medications

Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers

RESILIENT was a single arm, open label, phase II/III study to test if label agnostic therapy regimens guided by Encyclopedic Tumor Analysis can offer meaningful clinical benefit for patients with relapsed refractory metastatic malignancies. Patients with advanced refractory solid organ malignancies where disease had progressed following 2 lines of systemic treatments were enrolled in the […]

Medications

Dipeptidyl peptidase-4 inhibitors may up pancreatic disease risk

(HealthDay)—Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) is associated with increased risks for pancreatitis and pancreatic cancer in patients with newly diagnosed type 2 diabetes, according to a study published online Aug. 20 in Diabetes Care. Minyoung Lee, M.D., from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues used the Korean National […]

Medications

Taking buprenorphine for opioid use disorder may up other med compliance

(HealthDay)—Using buprenorphine to treat opioid use disorder (OUD) may increase adherence to treatments for other chronic conditions, according to a study published in the September issue of Medical Care. Hsien-Yen Chang, Ph.D., from Johns Hopkins University in Baltimore, and colleagues used Truven Health’s MarketScan data to identify 12,719 commercially insured individuals with a diagnosis of […]

Medications

OxyContin maker Purdue agrees to provide research data

The maker of the powerful painkiller OxyContin has agreed to provide access to propriety research and other data to researchers at Oklahoma State University to help them find causes and treatments for drug addiction. Stamford, Connecticut-based Purdue Pharma announced the agreement Thursday in a joint statement with the university. Purdue said it will provide Oklahoma […]